Latest News on SMMT

Financial News Based On Company


Advertisement
Advertisement

Summit Therapeutics launches Phase III trial of ivonescimab in Stage III NSCLC

https://www.streetinsider.com/Corporate+News/Summit+Therapeutics+launches+Phase+III+trial+of+ivonescimab+in+Stage+III+NSCLC/27366125.html
Summit Therapeutics has initiated HARMONi-10, a new global Phase III clinical trial for its investigational drug ivonescimab. The trial will evaluate ivonescimab as a consolidation therapy for patients with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed after chemoradiation, comparing it against durvalumab. This marks Summit's sixth Phase III study for ivonescimab, a bispecific antibody invented by Akeso Inc. and already approved in China.

Summit Therapeutics downgraded by Bernstein with a new price target

https://www.quantisnow.com/insight/summit-therapeutics-downgraded-by-bernstein-with-a-new-price-target-6797976
Bernstein has downgraded Summit Therapeutics (SMMT) to Underperform from Market Perform and set a new price target of $8.30. This downgrade reflects a more bearish outlook on the company. The article also provides historical stock performance after previous headlines and information on what an analyst downgrade signifies.

Summit cut to Underperform at Bernstein on R&D capabilities

https://seekingalpha.com/news/4674259-summit-stock-cut-underperform-bernstein
Bernstein downgraded Summit Therapeutics (SMMT) to Underperform from Market Perform. The downgrade was based on concerns about the company's R&D capabilities following the FDA's refusal to approve its lead asset, ivonescimab, which was developed in partnership with Akeso (AKESF).

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

https://www.marketwatch.com/story/summit-therapeutics-stock-tumbles-again-as-fda-recommends-new-trial-for-lung-cancer-drug-dcb8ff55
Summit Therapeutics' stock fell significantly after the FDA recommended a new clinical trial for its experimental lung-cancer drug, ivonescimab. The company had initially hoped for approval of ivonescimab in combination with chemotherapy for EGFR-mutated non-small-cell lung cancer, but the regulator decided against it. This decision, announced Sunday, led to a further tumble in the company's shares.

Summit Therapeutics sinks 16% after the FDA rejects ivonescimab over survival data

https://www.quantisnow.com/articles/summit-falls-16-after-fda-rejects-ivonescimab-signals-higher-survival-bar
Summit Therapeutics' stock plummeted 16.44% after the FDA rejected its drug ivonescimab for EGFR-mutated non-small cell lung cancer, citing a lack of statistically significant overall survival improvement in the HARMONi trial. This decision closes the immediate path to a U.S. launch for its only drug and raises concerns for its larger first-line lung cancer program, as analysts suggest the FDA is setting a higher efficacy bar requiring a survival gain, not just delayed tumor growth. The company, which reported $613 million in net losses for the first nine months of 2026 and no product revenue, now faces uncertainty regarding future U.S. approval.
Advertisement

Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback

https://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-hits-52-022043094.html
Summit Therapeutics (SMMT) shares hit a new 52-week low after the FDA rejected its Biologics License Application (BLA) for lung cancer treatment candidate, Ivonescimab. The rejection was due to a lack of substantial evidence of effectiveness, specifically an absence of statistically significant improvement in overall survival data, despite meeting the primary endpoint of progression-free survival in a Phase 3 trial. The company's CEO expressed disappointment but affirmed continued belief in Ivonescimab's potential and further development.

Why Is Summit Therapeutics Stock Plunging Today? - Summit Therapeutics (NASDAQ:SMMT)

https://www.benzinga.com/news/fda/26/11/63284061/summit-therapeutics-faces-fda-hurdle-for-lead-lung-cancer-drug-stock-tumbles
Summit Therapeutics (NASDAQ:SMMT) stock is plummeting after the FDA rejected its Biologics License Application (BLA) for ivonescimab, its lead lung cancer drug. The FDA cited a lack of statistically significant overall survival data, although progression-free survival was met. Despite the setback, a post-hoc analysis showed a consistent overall survival benefit across patient populations.

Summit shares drop after US FDA declines to approve lung cancer drug

https://www.reuters.com/legal/litigation/summit-shares-drop-after-us-fda-declines-approve-lung-cancer-drug-2026-11-16/
Shares of Summit Therapeutics fell nearly 20% in premarket trading after the US FDA declined to approve its experimental lung cancer drug, ivonescimab, citing a failure to achieve statistical significance in overall survival in a late-stage study. This decision sets a regulatory precedent for similar drugs, though analysts note it does not impact the drug's prospects for first-line treatment of non-small cell lung cancer, which is a larger commercial opportunity. Summit had acquired rights to the drug from China's Akeso in 2022.

SMMT: Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

https://www.quantisnow.com/insight/summit-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6792001
Summit Therapeutics Inc. (SMMT) has filed an SEC Form 8-K reporting on "Other Events, Financial Statements and Exhibits." This filing comes after the FDA issued a Complete Response Letter on ivonescimab BLA for EGFR-TKI-pretreated NSCLC, citing no statistically significant overall survival. The article also provides historical stock performance after previous SMMT headlines.

FDA rejects Summit Therapeutics BLA for ivonescimab in lung cancer

https://www.streetinsider.com/Corporate+News/FDA+rejects+Summit+Therapeutics+BLA+for+ivonescimab+in+lung+cancer/27347016.html
The FDA has issued a Complete Response Letter (CRL) for Summit Therapeutics' Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for non-small cell lung cancer (NSCLC). The FDA cited a lack of statistically significant overall survival improvement, indicating that progression-free survival benefit alone did not support a positive benefit-risk profile. Summit Therapeutics expressed disappointment but plans to continue developing ivonescimab for various cancer types.
Advertisement

FDA rejects Summit Therapeutics and Akeso's lung cancer drug ivonescimab, saying it needs an overall survival benefit

https://mlq.ai/news/fda-rejects-summit-therapeutics-and-akesos-lung-cancer-drug-ivonescimab-saying-it-needs-an-overall-survival-benefit/
The FDA has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab, stating that its effectiveness was not established without a statistically significant overall survival benefit. The decision follows the HARMONi trial, which met its progression-free survival (PFS) endpoint but showed only a positive trend in overall survival that did not reach statistical significance. Summit Therapeutics expressed disappointment but indicated that development of the drug, which is already approved in China, will continue.

Summit Therapeutics reports FDA refusal for ivonescimab

https://mugglehead.com/summit-therapeutics-ivonescimab-fda-refusal-survival/
Summit Therapeutics announced that the FDA has declined approval for its lung cancer treatment, ivonescimab, when combined with chemotherapy. The FDA concluded that the progression-free survival benefit observed in the HARMONi trial was not sufficient to establish a positive benefit-risk profile without a statistically significant improvement in overall survival. This decision delays potential U.S. sales, though Summit has other trials and a strong cash position to continue its development programs.

Summit Therapeutics Inc Stock (SMMT) Moved Down by 7.27% on Nov 12: Drivers Behind the Movement

https://www.tradingkey.com/news/market-movers/262303203-market-movers-smmt-20261112
Summit Therapeutics Inc. (SMMT) experienced a 7.27% stock decline on November 12, driven by investor de-risking ahead of a critical mid-November regulatory decision for its lead drug, ivonescimab. Market caution stemmed from uncertainty regarding regulatory approval, the robustness of clinical trial data, and the company's pre-commercial financial burn. Technical indicators show a neutral MACD and RSI but a Williams %R sell signal, while the company maintains no commercial revenue and significant R&D expenses.

Summit sheds commercial leaders ahead of ivonescimab's FDA decision

https://www.fiercepharma.com/pharma/summits-commercial-and-market-leadership-gaps-pdufa-decision-looms
Summit Therapeutics has lost its chief commercial officer, Robert LaCaze, and several other commercial and marketing leaders just before the FDA's decision on its drug, ivonescimab, for non-small cell lung cancer. The company downplayed the departures as routine while sources close to the company indicate that "long-term players" responsible for launch planning were let go. This comes as the FDA decision is uncertain, given the drug's global HARMONi trial missed its overall survival endpoint.

Summit Therapeutics Stock Losses Narrow As Share Increase Is Approved

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-stock-losses-narrow-as-share-increase-is
Summit Therapeutics reported a narrowed net loss of US$208.39 million for Q3 2026, with a nine-month loss of US$613.51 million. Shareholders approved an increase in authorized common stock to 2 billion shares, providing the company with more options to raise capital for its ivonescimab program and late-stage pipeline, though this introduces potential dilution risk for investors. Analysts forecast a significant earnings swing by 2029, projecting US$1.2 billion in revenue and US$197.7 million in earnings, compared to current losses.
Advertisement

Stifel cuts Summit Therapeutics stock price target on valuation By Investing.com

https://uk.investing.com/news/stock-market-news/stifel-cuts-summit-therapeutics-stock-price-target-on-valuation-93CH-4962037
Stifel has lowered its price target for Summit Therapeutics (NASDAQ:SMMT) to $37 from $38, while maintaining a Buy rating, citing valuation concerns. This adjustment follows the company's Q3 2026 earnings, which highlighted promising ivonescimab data and accelerated enrollment in colorectal cancer trials, alongside the closing of AstraZeneca's $2 billion investment. Despite these positive developments and strong liquidity, analysts do not expect Summit Therapeutics to achieve profitability this year.

Summit Therapeutics Q3 Results: Adj. EPS of $(0.20) beats estimates

https://scanx.trade/stock-market-news/companies/summit-therapeutics-q3-results-adj-eps-0-20-beats-estimates/55386281
Summit Therapeutics reported an adjusted loss per share of $(0.20) for the third quarter, which surpassed analyst estimates of $(0.28). While this represents a 28.57% improvement over expected figures, the year-over-year loss widened by 53.85% from $(0.13) per share in the prior period. Despite beating market expectations, the underlying operational performance showed a decline compared to the previous year.

Form 8-K Summit Therapeutics Inc. For: Nov 04

https://www.streetinsider.com/SEC+Filings/Form+8-K+Summit+Therapeutics+Inc.+For%3A+Nov+04/27291455.html
Summit Therapeutics Inc. filed a Form 8-K on November 4, 2026, announcing its third-quarter 2026 financial results and operational progress. The company's stockholders also approved an amendment to increase the authorized shares of common stock from 1 billion to 2 billion, effective upon filing with the Delaware Secretary of State.

AstraZeneca invested $2B in Summit Therapeutics (SMMT), which reported a narrower Q3 loss.

https://www.stocktitan.net/sec-filings/SMMT/10-q-summit-therapeutics-inc-quarterly-earnings-report-ab400e5658b5.html
Summit Therapeutics reported a narrower net loss of $208.4 million in Q3 2026, down from $231.8 million a year earlier, and a nine-month net loss of $613.5 million. The company's cash position was significantly bolstered by a $2.0 billion investment from AstraZeneca, which closed in October 2026, and it continues to advance its lead drug candidate, ivonescimab, in multiple oncology clinical trials. The FDA has set a November 14, 2026, goal action date for ivonescimab's Biologics License Application (BLA) for EGFR-mutated NSCLC, with a requirement for statistically significant overall survival benefit.

Form 8K Summit Therapeutics PLC ADR For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-summit-therapeutics-plc-adr-for-4-november-93CH-4932143
This article reports on the filing of a Form 8K by Summit Therapeutics PLC ADR on November 4, 2026. The financial instrument SMMT is mentioned with a 2.34% increase. The content appears to be a brief announcement of the filing rather than an in-depth analysis.
Advertisement

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

https://quantisnow.com/insight/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-6773225
Summit Therapeutics reported a narrowed GAAP net loss of $208.4 million for Q3 2026, or $(0.26) per share, an improvement from $231.8 million year-over-year. The company received a $2.0 billion equity investment from AstraZeneca post-quarter end, boosting its cash and investments to $629.8 million at quarter end. A key upcoming event for shareholders is the FDA's PDUFA goal date of November 14, 2026, for ivonescimab.

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

https://www.quantisnow.com/insight/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-6773225
Summit Therapeutics reported a GAAP net loss of $208.4 million, or $(0.26) per share, for the third quarter of 2026, a decrease from $231.8 million a year prior. The company significantly boosted its cash reserves by $2.0 billion from an AstraZeneca equity investment post-quarter-end, bringing total cash and investments to $629.8 million. A key upcoming event for shareholders is the FDA's decision on ivonescimab, with a PDUFA goal date of November 14, 2026.

Summit Therapeutics files legal opinion for common stock issuance

https://www.investing.com/news/sec-filings/summit-therapeutics-files-legal-opinion-for-common-stock-issuance-93CH-5001733
Summit Therapeutics (NASDAQ:SMMT) announced the filing of a prospectus supplement with the SEC, including a legal opinion from Baker & Hostetler LLP regarding the issuance of common stock. This filing follows recent analyst ratings and a significant $2 billion investment from AstraZeneca, reflecting a complex but active period for the company.

Summit Therapeutics plc (SMMT) Seasonal returns chart

https://uk.finance.yahoo.com/quote/SMMT/seasonality/
The article presents a seasonal returns chart for Summit Therapeutics plc (SMMT), showing the average monthly price return between 2016 and 2026. It indicates the stock's current price and pre-market activity, alongside links to other financial data like news, statistics, and historical performance.

Precision Trading with Summit Therapeutics Inc. (SMMT) Risk Zones

https://news.stocktradersdaily.com/news_release/8/Precision_Trading_with_Summit_Therapeutics_Inc._SMMT_Risk_Zones_102626093201_1793021521.html
Summit Therapeutics Inc. (SMMT) is showing strong near-term sentiment despite prevailing mid and long-term weakness. The stock is currently testing support, with an exceptional 97.0:1 risk-reward setup targeting a 25.4% gain against 0.3% risk. AI models have generated distinct trading strategies, including Position Trading, Momentum Breakout, and Risk Hedging, to guide institutional trading based on varying risk profiles and holding periods.
Advertisement

Summit Therapeutics reports 25% lower death risk in biliary-cancer trial

https://mugglehead.com/summit-therapeutics-ivonescimab-biliary-cancer-survival-china/
Summit Therapeutics announced that its drug ivonescimab, combined with chemotherapy, reduced the risk of death by 25% in a Chinese Phase 3 biliary-cancer trial. The study showed an extension of median survival to 14.9 months compared to 12.1 months with the active comparator. Summit plans to initiate a separate U.S. Phase 2/3 trial in the fourth quarter of 2026.

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

https://www.financialcontent.com/article/bizwire-2026-10-25-ivonescimab-plus-chemotherapy-demonstrates-overall-survival-superiority-compared-to-durvalumab-plus-chemotherapy-in-first-line-treatment-of-patients-with-advanced-biliary-tract-cancer-in-harmoni-gi1-study-conducted-by-akeso-in-china
Akeso Inc. announced positive results from its Phase III HARMONi-GI1 study, showing that ivonescimab plus chemotherapy significantly improved overall survival and progression-free survival compared to durvalumab plus chemotherapy in patients with advanced biliary tract cancer (BTC). This marks the first known Phase III study in advanced BTC to demonstrate overall survival superiority over an anti-PD-(L)1 therapy combined with chemotherapy. Summit Therapeutics, Akeso's partner, noted these findings, which will support a U.S. registration-enabling Phase II/III study of ivonescimab in BTC starting in Q4 2026.

AI will be tested on routine cancer slides for clues about treatment response.

https://www.stocktitan.net/news/SMMT/summit-therapeutics-and-lunit-announce-agreement-to-apply-ai-powered-j3n91jgvbu28.html
Summit Therapeutics and Lunit Inc. have entered a research agreement to utilize Lunit's AI-powered pathology platform, Lunit SCOPE IO, for analyzing tumor microenvironment in support of Summit's ivonescimab immuno-oncology development programs. The collaboration aims to extract insights from routine tissue images to aid biomarker discovery, patient stratification, and enhance understanding of treatment response without needing additional stains or assays. This initiative underscores the growing role of computational pathology in oncology drug development.

Summit Therapeutics plc (SMMT) options chain

https://uk.finance.yahoo.com/quote/SMMT/options/?date=1797552000&straddle=false&type=all
This article provides detailed options chain data for Summit Therapeutics plc (SMMT) as of October 28, 2026. It lists call and put options expiring on December 18, 2026, including strike prices, last trade dates, last prices, volumes, and implied volatility. The current stock price for SMMT is also noted, showing its performance at close and during overnight trading.

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

https://www.prnewswire.com/news-releases/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development-302918571.html
Lunit Inc. and Summit Therapeutics Inc. have announced a research agreement to utilize Lunit SCOPE IO, Lunit's AI-powered pathology platform, for analyzing the tumor microenvironment in Summit's immuno-oncology development programs with ivonescimab. This collaboration aims to enhance biomarker discovery, patient stratification, and deepen the understanding of responses to ivonescimab therapies by generating scalable insights from routine tissue samples. The agreement highlights the growing significance of computational pathology in oncology drug development, providing a way to extract high-dimensional biomarker data from H&E slides.
Advertisement

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

https://www.thailand-business-news.com/pr-news/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development
Lunit Inc. and Summit Therapeutics Inc. have announced a research agreement to use Lunit SCOPE IO, an AI-powered pathology platform, for tumor microenvironment analysis in Summit's immuno-oncology programs with ivonescimab. This collaboration aims to leverage AI to analyze H&E whole-slide images, supporting biomarker discovery, patient stratification, and a deeper understanding of treatment response. The agreement highlights the increasing role of computational pathology in oncology drug development, enabling scalable and reproducible high-dimensional biomarker data extraction from routine tissue samples.

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold Rating

https://www.moomoo.com/news/post/1002217782/hc-wainwright-maintains-summit-therapeutics-smmtus-with-hold-rating
H.C. Wainwright has reiterated its Hold rating on Summit Therapeutics (SMMT.US). This action suggests that the firm sees no immediate significant upside or downside for the stock at its current valuation.

Summit Therapeutics Inc. Estimates – NASDAQ:SMMT

https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-estimates/?category=cash_flow
This page provides financial estimates for Summit Therapeutics Inc. (NASDAQ: SMMT) on TradingView. Users can explore reported financial data and analyst estimates across various statements, compare actual results with estimates, and visualize trends. The platform also offers disclaimers regarding investment advice and encourages users to conduct their own research.

Summit Therapeutics and Lunit partner on AI pathology for cancer research

https://www.streetinsider.com/Corporate+News/Summit+Therapeutics+and+Lunit+partner+on+AI+pathology+for+cancer+research/27228339.html
Summit Therapeutics and Lunit Inc. have announced a research agreement to utilize Lunit's AI-powered pathology platform, Lunit SCOPE IO, for tumor microenvironment analysis. This collaboration aims to support Summit's immuno-oncology development programs involving ivonescimab, focusing on biomarker discovery, patient stratification, and understanding responses to therapies. The platform analyzes standard tissue slides without additional stains, providing insights for future translational research and clinical development.

Positive survival findings from an experimental cancer treatment will lead 10 talks in Madrid

https://www.stocktitan.net/news/SMMT/ivonescimab-data-sets-across-multiple-tumor-types-to-be-featured-at-54y6hegdbtp3.html
Summit Therapeutics announced that data for its experimental cancer treatment, ivonescimab, will be featured in 10 presentations at the European Society for Medical Oncology (ESMO) 2026 Congress. The presentations include positive overall survival findings from a Phase III study in biliary tract cancer and promising Phase II data in endometrial cancer, supporting further clinical development. These findings highlight the expanding evidence for ivonescimab across various tumor types, demonstrating its potential to make a meaningful difference for patients.
Advertisement

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

https://www.manilatimes.net/2026/10/21/tmt-newswire/pr-newswire/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer/2450970
Akeso, Inc. announced a clinical trial collaboration between its global partner Summit Therapeutics Inc. and the ECOG-ACRIN Cancer Research Group. This collaboration will evaluate ivonescimab in a Phase II/III study (EA2251) for first-line treatment of advanced biliary tract cancer, marking the 7th international registrational trial for ivonescimab. This follows positive overall survival results from Akeso's Phase III HARMONi-GI1 study in China for the same indication.

Summit Therapeutics begins biliary tract cancer trial for ivonescimab

https://www.investing.com/news/company-news/summit-therapeutics-begins-biliary-tract-cancer-trial-for-ivonescimab-93CH-4963098
Summit Therapeutics has initiated a Phase II/III clinical trial in collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab for the first-line treatment of advanced biliary tract cancer. This study, designated EA2251, will compare ivonescimab with chemotherapy against existing immunotherapy-based standards of care. The drug, a PD-1/VEGF bispecific antibody developed by Akeso, has shown positive overall survival results in a previous Phase III study in China.

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

https://investingnews.com/summit-therapeutics-announces-opening-of-global-phase-ii-study-of-ivonescimab-based-regimens-in-advanced-clear-cell-renal-cell-carcinoma/
Summit Therapeutics has initiated a global Phase II study (SMT112-216) of ivonescimab-based regimens for previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study, in collaboration with Akeso Inc., will evaluate ivonescimab alone and in combination with other therapies against a standard-of-care comparator. This expands Summit's ivonescimab development program beyond lung cancer into genitourinary malignancies, leveraging the drug's dual PD-1/VEGF targeting mechanism.

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

https://www.biospace.com/press-releases/summit-therapeutics-announces-opening-of-global-phase-ii-study-of-ivonescimab-based-regimens-in-advanced-clear-cell-renal-cell-carcinoma
Summit Therapeutics (NASDAQ: SMMT) has initiated a global Phase II study (SMT112-216) for ivonescimab, a bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC). The study, conducted in collaboration with Akeso, will evaluate ivonescimab alone and in combination with cadonilimab or ipilimumab, as well as nivolumab plus ipilimumab as a comparator, across sites in the U.S. and China. This expands Summit's ivonescimab development program beyond lung cancer, targeting a significant unmet medical need in kidney cancer.

A share-increase proposal at Summit Therapeutics (SMMT) would help enable conversion of $2B in preferred stock.

https://www.stocktitan.net/sec-filings/SMMT/def-14a-summit-therapeutics-inc-definitive-proxy-statement-858e6a1e7501.html
Summit Therapeutics is proposing to increase its authorized common shares by 1 billion, from 1 billion to 2 billion, to facilitate the conversion of $2 billion in Class A Preferred Stock issued in a recent private placement. The board unanimously recommends a "FOR" vote at the November 4, 2026, special meeting, as failure to approve the amendment by December 31, 2026, could lead to mandatory cash redemption of the preferred stock and negatively impact the company's financial flexibility. The increase would also provide shares for future capital raising, equity incentives, and other corporate purposes.
Advertisement

Summit Therapeutics Inc. (SMMT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/SMMT/latest-news/
This article provides a financial overview of Summit Therapeutics Inc. (SMMT), including its stock price, recent news, and performance. It highlights the company's collaboration with AstraZeneca on Ivonescimab development for cancer treatment. The stock's performance metrics are also presented, showing a significant three-year return despite recent short-term declines.

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

https://finance.yahoo.com/healthcare/articles/summit-therapeutics-announces-opening-global-110000235.html
Summit Therapeutics has initiated a global Phase II study (SMT112-216) for ivonescimab, a bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC). The study, in collaboration with Akeso, will evaluate ivonescimab alone and in combination with cadonilimab or ipilimumab, enrolling approximately 100 patients across clinical sites in the U.S. and China. This expansion into genitourinary malignancies underscores Summit's strategy to broaden ivonescimab's development beyond lung cancer.

Form 4 Summit Therapeutics PLC ADR: Bhaskar Anand (Chief Accounting Officer) For: 8 October

https://ng.investing.com/news/stock-market-news/form-4-summit-therapeutics-plc-adr-bhaskar-anand-chief-accounting-officer-for-8-october-93CH-2737297
This article reports a Form 4 filing for Summit Therapeutics PLC ADR, detailing a transaction by Bhaskar Anand, the Chief Accounting Officer, on October 8th. The filing is a standard disclosure of insider trading activity.

Accounting chief gets a stock grant at Summit Therapeutics (SMMT), vesting in 2029 if still employed.

https://www.stocktitan.net/sec-filings/SMMT/form-4-summit-therapeutics-inc-insider-trading-activity-cab0edc647ea.html
Summit Therapeutics Inc.'s Chief Accounting Officer, Bhaskar Anand, was granted 100,000 restricted stock units on October 8, 2026. These units will vest on October 8, 2029, contingent on his continued employment with the company, and each vested unit converts into one common share. Following this grant, Anand's direct holdings in SMMT totaled 261,047 shares.

Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled

https://www.tradingkey.com/news/market-movers/262214653-market-movers-smmt-20261013
Summit Therapeutics Inc. (SMMT) stock fell by 8.61% on October 13 due to profit-taking following a recent rally, increased investor caution ahead of critical Phase III clinical data readouts and a Prescription Drug User Fee Act (PDUFA) action date, and concerns over potential share dilution from a proposed common share count expansion. Despite the decline, long-term market sentiment remains positive due to strategic partnerships and ongoing multi-indication trials. Technical indicators show a neutral to oversold condition, while fundamental analysis highlights the company's pre-revenue status and high dependence on its single clinical asset, ivonescimab.
Advertisement

Summit Therapeutics Inc. (SMMT) Options Chain

https://ca.finance.yahoo.com/quote/SMMT/options/?date=1791504000&straddle=true
The article displays the options chain for Summit Therapeutics Inc. (SMMT) on Yahoo Finance. As of October 9, 2026, the stock price was 17.20, down 4.19%. The options chain indicates that there are currently no options available for SMMT.

Summit Therapeutics Rises as Investors Continue to Digest AstraZeneca Deal

https://www.quiverquant.com/news/Summit+Therapeutics+Rises+as+Investors+Continue+to+Digest+AstraZeneca+Deal
Summit Therapeutics (SMMT) saw a 3.9% increase, likely due to continued positive sentiment following AstraZeneca's $2.0 billion strategic equity investment, which closed on October 5, 2026. This capital infusion and collaboration agreements are expected to accelerate the development of ivonescimab and other oncology assets. Insider purchases and significant institutional investor activity also indicate strong confidence in SMMT.

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

https://pmlive.com/pharma_news/astrazeneca-and-daiichi-sankyo-to-collaborate-with-summit-therapeutics/
AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to evaluate the combination of Datroway (datopotamab) and ivonescimab for various cancer types, including lung and breast cancers. The collaboration aims to conduct a phase 3 trial for 1st-line triple-negative breast cancer (TNBC). Each company will contribute their respective medicines and share costs, retaining commercial rights to their own products.

A $2B financing leads Summit Therapeutics (SMMT) to ask investors for more authorized shares.

https://www.stocktitan.net/sec-filings/SMMT/pre-14a-summit-therapeutics-inc-preliminary-proxy-statement-389d1a7f0f59.html
Summit Therapeutics (SMMT) is seeking stockholder approval to increase its authorized common shares by 1 billion, from 1 billion to 2 billion, to facilitate the conversion of preferred shares issued in a recent $2 billion private placement. Without this approval by December 31, 2026, the company risks being unable to convert the preferred shares, potentially leading to significant financial obligations and hindering future capital-raising strategies. The board unanimously recommends a "FOR" vote, emphasizing the importance of this amendment for financial flexibility and continued operations.

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

https://www.citybiz.co/article/913701/astrazeneca-completes-2-billion-equity-investment-in-summit-therapeutics/
AstraZeneca has finalized a $2 billion equity investment in Summit Therapeutics, acquiring approximately 108,955 shares of Summit preferred stock. This capital injection aims to accelerate the development of Summit's investigational cancer therapy, ivonescimab, for various solid tumor indications. The investment underscores AstraZeneca's confidence in ivonescimab's potential and will enable Summit to broaden its clinical program and approach significant regulatory milestones, including a target PDUFA decision date for a Biologics License Application in November 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement